⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CADL News
Candel Therapeutics, Inc. Common Stock
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
globenewswire.com
CADL
Form 8-K
sec.gov
CADL
Form 8-K
sec.gov
CADL
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
globenewswire.com
CADL
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CADL
Form 8-K
sec.gov
CADL
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
globenewswire.com
CADL
Form 8-K
sec.gov
CADL
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com
CADL
Candel Therapeutics to Present at Upcoming Investor Conferences
globenewswire.com
CADL